ATTAINMENT OF LDL-C TREATMENT TARGET IN FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS: A THEORETICAL MODEL EXPLORING EFFICACY OF CURRENT AND NOVEL LIPID LOWERING THERAPIES

被引：1
|
作者：
Hartgers, M. L. [1 ]
Besseling, J. [1 ]
Hovingh, G. K. [1 ]
机构：
[1] Acad Med Ctr, Vasc Med, Amsterdam, Netherlands
来源：
ATHEROSCLEROSIS | 2016年 / 252卷
关键词：
D O I：
10.1016/j.atherosclerosis.2016.07.372
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
EAS16-0724
引用
收藏
页码：E43 / E44
页数：2
相关论文
共 50 条
  • [31] Lapaqistat acetate monotherapy: Effects of a novel squalene synthase inhibitor on LDL-C levels and other lipid parameters in patients with primary hypercholesterolemia
    Bays, Harold E.
    Weiss, Robert J.
    Rhyne, James M.
    Chen, Yinzhong
    Lopez, Claudia
    Spezzi, Andrea H.
    CIRCULATION, 2007, 116 (16) : 127 - 127
  • [32] Different perspectives of patients and physicians on LDL-C target achievement in the treatment of hypercholesterolemia: results on secondary prevention from the German PROCYON survey
    Weingaertner, O.
    Beier, L.
    Stein, K.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2541 - 2541
  • [33] Different Perspectives of Patients and Physicians on LDL-C Target Achievement in the Treatment of Hypercholesterolemia: Results on Secondary Prevention from the German PROCYON Survey
    Makhmudova, Umidakhon
    Wolf, Michaela
    Willfeld, Kathy
    Beier, Lea
    Weingaertner, Oliver
    ADVANCES IN THERAPY, 2023, 40 (02) : 460 - 473
  • [34] Different Perspectives of Patients and Physicians on LDL-C Target Achievement in the Treatment of Hypercholesterolemia: Results on Secondary Prevention from the German PROCYON Survey
    Umidakhon Makhmudova
    Michaela Wolf
    Kathy Willfeld
    Lea Beier
    Oliver Weingärtner
    Advances in Therapy, 2023, 40 : 460 - 473
  • [35] Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry
    Vrablik, Michal
    Raslova, Katarina
    Vohnout, Branislav
    Blaha, Vladimir
    Satny, Martin
    Kyselak, Ondrej
    Vaclova, Martina
    Urbanek, Robin
    Maskova, Jana
    Soska, Vladimir
    Freiberger, Tomas
    ATHEROSCLEROSIS, 2018, 277 : 355 - 361
  • [36] TREATMENT PATTERNS AND LDL-C CONTROL IN VERY HIGH-RISK PATIENTS RECEIVING LIPID-LOWERING THERAPY IN THE UNITED KINGDOM
    Beaini, Y.
    Danese, M.
    Sidelnikov, E.
    Villa, G.
    Catterick, D.
    Iqbal, M.
    Gleeson, M.
    Lubeck, D.
    Patel, J.
    VALUE IN HEALTH, 2020, 23 : S499 - S500
  • [37] THE EFFICACY OF EVOLOCUMAB AND OTHER LIPID-LOWERING THERAPIES (LLT) FOR THE MANAGEMENT OF LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C): A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS (NMA)
    Worthy, G.
    Gandra, S. R.
    Bridges, I.
    Worth, G.
    Dent, R.
    Cheng, L. I.
    Forbes, C.
    Deshpande, S.
    Ross, J.
    Kleijnen, J.
    Stroes, E. S. G.
    ATHEROSCLEROSIS, 2016, 252 : E56 - E57
  • [38] Apheresis Treatment does not Affect the Lipid-Lowering Efficacy of Lomitapide, a Microsomal Triglyceride Transfer Protein Inhibitor, in Patients with Homozygous Familial Hypercholesterolemia
    Cuchel, Marina
    Meagher, Emma A.
    Theron, H. du Toit
    Blom, Dirk
    Marais, A. D.
    Hegele, Robert A.
    Averna, Maurizio
    Sirtori, Cesare
    Shah, Prediman K.
    Gaudet, Daniel
    Stefanutti, Claudia
    Vigna, Giovanni B.
    du Plessis, A. M. E.
    Bloedon, LeAnne T.
    Rader, Daniel J.
    CIRCULATION, 2012, 126 (21)
  • [39] The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis (vol 41, pg 837, 2024)
    Alshahrani, Awad
    Kholaif, Naji
    Al-Khnifsawi, Mutaz
    Zarif, Hawazen
    Mahzari, Moeber
    ADVANCES IN THERAPY, 2024, 41 (05) : 2083 - 2083
  • [40] Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
    John J. P. Kastelein
    Jennifer G. Robinson
    Michel Farnier
    Michel Krempf
    Gisle Langslet
    Christelle Lorenzato
    Daniel A. Gipe
    Marie T. Baccara-Dinet
    Cardiovascular Drugs and Therapy, 2014, 28 : 281 - 289
12345